2018 Nobel Prize in Medicine Awarded for Discovery in Cancer Treatment

2018 Nobel Prize in Medicine Awarded for Discovery in Cancer Treatment
2018 Nobel Prize in Medicine Awarded for Discovery in Cancer Treatment
Anonim

Immunologists James Ellison of the United States and Tasuku Honjo of Japan received the 2018 Nobel Prize in Medicine for research that revolutionized cancer treatment.

Nobel Prize in Medicine 2018

Scientists have been awarded for discovering cancer treatments by suppressing negative immune regulation, according to the Nobel Committee.

Immunity checkpoint inhibition therapy targets proteins produced by some cells of the immune system as well as some cancer cells. These proteins can prevent the body's natural defense mechanisms from killing cancer cells. Therapy is designed to break this protein brake so that the immune system can quickly begin fighting cancer.

University of Texas professor James Ellison and Kyoto University professor Tasuku Honjo received the Tang Prize (Asian version of the Nobel Prize) for their research. The scientists will share the prize fund, the amount of which is nine million Swedish kronor (about 1.01 million dollars or 870 thousand euros).

The prize will be awarded to scientists by King Carl XVI Gustav at a ceremony that will traditionally take place in Stockholm on December 10, on the anniversary of the death of Alfred Nobel, the founder of the prize.

Last year, American geneticists Jeffrey Hall, Michael Rosbash and Michael Young received medical awards for their research on the role of genes in the "circadian rhythm" that regulates sleep, dietary patterns, hormones and body temperature.

The 2018 Nobel Prize Winners in Physics will be announced on Tuesday, and the Chemistry Prize Winners on Wednesday. The Peace Prize will be announced on Friday and the Economics Prize will close the Nobel season on Monday 8 October.

For the first time since 1949, the Swedish Academy postponed the announcement of the Nobel Prize in Literature until next year amid the #MeToo scandal and due to internal litigation.

Popular by topic